News
Roche’s gene therapy unit Spark has added to its pipeline in inherited retinal diseases (IRDs) with a $216 million alliance with Spanish biotech SpliceBio.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback